Navigation Links
FDA OKs Expanded Use of Prostate Cancer Drug
Date:12/10/2012

MONDAY, Dec. 10 (HealthDay News) -- The approved use of the drug Zytiga has been expanded to include treatment of men with late-stage, hormone therapy-resistant prostate cancer before they undergo chemotherapy, the U.S. Food and Drug Administration announced Monday.

Zytiga was initially approved in April 2011 for treatment of prostate cancer patients whose disease had progressed after treatment with the chemotherapy drug docetaxel.

The drug decreases production of the male sex hormone testosterone. In prostate cancer, testosterone stimulates prostate tumors to grow. Drugs or surgery are used to reduce testosterone production or to block the hormone's effects.

However, some men have what's called "castration-resistant" or hormone therapy-resistant prostate cancer, which means that prostate cancer cells continue to grow even with low levels of testosterone, the FDA explained in a news release.

The expanded approval is based on a study of 1,088 men with late-stage, hormone therapy-resistant prostate cancer who took either Zytiga (abiraterone acetate) or an inactive placebo in combination with another drug called prednisone.

Median overall survival was just over 35 months for patients who took Zytiga and about 30 months for those who took the placebo, the FDA noted.

The most common side effects among patients taking Zytiga included fatigue, joint discomfort, swelling caused by fluid retention, hot flush, diarrhea, vomiting, cough, high blood pressure, shortness of breath, urinary tract infection and bruising.

This expanded approval of Zytiga was made under the FDA's priority review program, which offers an accelerated six-month review for drugs that may offer major advances in treatment or provide a treatment when no adequate therapy exists.

"Today's approval demonstrates the benefit of further evaluating a drug in an earlier disease setting and provides patients and health care providers the option of using Zytiga earlier in the course of treatment," Dr. Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research, said in the FDA news release.

Zytiga is marketed by Pennsylvania-based Janssen Biotech Inc.

More information

The American Cancer Society has more about prostate cancer.

-- Robert Preidt

SOURCE: U.S. Food and Drug Administration, news release, Dec. 10, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Prostate cancer now detectable by imaging-guided biopsy
2. Targeted prostate biopsy has potential to improve diagnosis of prostate cancer
3. The Project for Natural Health Choices Inc. Issues an Advisory for Men to Consume Flavonoids in their Diet to Protect Against Prostate Cancer
4. Targeted Prostate Cancer Biopsies Might Improve Care: Study
5. Longer life expectancy, aging population necessitate new strategies for prostate cancer care
6. Drug shows promise in prostate cancer spread to bone
7. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
8. COUP-TFII sparks prostate cancer progression
9. UAlberta prostate cancer researcher and team developing homing beacon drugs to target cancer cells
10. Prostate Cancer Websites Often Hard to Understand: Study
11. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2019)... ... November 14, 2019 , ... EMulate Therapeutics, Inc., ... diseases, announced it will have 5 poster presentations related to its medical devices ... for Neuro-Oncology SNO Meeting in Phoenix, beginning on November 20 . ...
(Date:11/14/2019)... ... 14, 2019 , ... AstraZeneca and MSD (Merck) announced today ... status of its application for the MEK inhibitor selumetinib, for use in patients ... The FDA’s acceptance of the application is a major milestone for selumetinib becoming ...
(Date:11/12/2019)... , ... November 12, 2019 , ... AI for preventable ... KLAS report “Healthcare AI 2019 - Actualizing the Potential of AI”, which provides ... leader and the only healthcare-focused AI company with enough clients to complete a full ...
(Date:11/12/2019)... , ... November 12, 2019 , ... ... clinical study. With increasing site activation cycle times, extended contract negotiations and 80 ... is an area of clinical operations that’s ripe for improvement. Following an overview ...
(Date:11/11/2019)... ... ... Early praise for A Nurse’s Step-by-Step Guide to Publishing a Dissertation or DNP Project: ... and vital guidance for publishing dissertations or DNP projects. A Nurse’s Step-by-Step Guide to ... and will be shared with new graduates and colleagues alike.” , -Nancy White ...
Breaking Medicine News(10 mins):
(Date:11/15/2019)... ... November 15, 2019 , ... JustCBD looks forward to working ... Warriors was founded by the military families aboard Marine Corps Base Camp Lejeune, ... and their families. For the past 13 years, Hope For The Warriors has been ...
(Date:11/14/2019)... TAUNTON, Mass. (PRWEB) , ... November 14, 2019 ... ... to offering innovative green, natural, clean, safe, and effective products to health and ... “Deodorant Product of the Year” award. , The award is presented by the ...
(Date:11/14/2019)... ... November 14, 2019 , ... ... the earliest stages of disease development or their recurrence, is attracting interest and ... Research Institute), now part of Nuvance Health, and the Icahn School of Medicine ...
Breaking Medicine Technology: